BeyondSpring Regains Compliance With Nasdaq Minimum Bid Price and Periodic Filing Requirements
BeyondSpring Regains Compliance With Nasdaq Minimum Bid Price and Periodic Filing Requirements
FLORHAM PARK, N.J., Feb. 26, 2024 (GLOBE NEWSWIRE) — BeyondSpring Inc. (NASDAQ: BYSI) ("BeyondSpring" or the "Company"), a global clinical-stage biopharmaceutical company focused on using a groundbreaking technology platform for drug discovery and developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs, today announced that on February 20, 2024, the Company received a written notification on minimum bid price compliance (the "Notification Letter") from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). In the Notification Letter, the staff of Nasdaq has determined that for the 10 consecutive business days from February 5, 2024 to February 16, 2024, the closing bid price of the Company's ordinary shares had been at $1.00 per share or greater. Accordingly, the bid price deficiency matter as previously disclosed is now closed.
新泽西州弗洛勒姆公园，2024年2月26日（环球新闻专线）— BeyondSpring Inc. 纳斯达克股票代码：BYSI）（“BeyondSpring” 或 “公司”）是一家全球临床阶段的生物制药公司，专注于使用突破性的技术平台进行药物发现和开发创新疗法，以改善未得到满足的医疗需求患者的临床疗效。该公司于2024年2月20日收到了纳斯达克股票市场有限责任公司的书面通知（“通知书”）（“通知书”）（“Nasdaq”）表示公司已恢复遵守中规定的最低出价要求《纳斯达克上市规则》5550 (a) (2)。纳斯达克工作人员在通知信中确定，在2024年2月5日至2024年2月16日的连续10个工作日内，公司普通股的收盘价为每股1.00美元或以上。因此，先前披露的出价缺陷问题现已结案。
In addition, on February 20, 2024, the Company received a written notification on periodic filing compliance (the "Letter") from Nasdaq that it has met the periodic filing requirement for Nasdaq Listing Rule 5250(c)(2) (the "Rule"). In the Letter, the staff of Nasdaq has determined the Company complies with the Rule as the Company filed its Form 6-K for the period ended June 30, 2023 on February 2, 2024. Accordingly, the filing delinquency matter as previously disclosed is now closed.
此外，2024年2月20日，公司收到纳斯达克关于定期申报合规性的书面通知（“信函”），称其已满足纳斯达克上市规则5250（c）（2）（“规则”）的定期申报要求。在这封信中，纳斯达克的工作人员确定公司遵守了该规则，因为该公司于2024年2月2日提交了截至2023年6月30日的6-K表格。因此，先前披露的拖欠申报事项现已结案。
About BeyondSpring
BeyondSpring (NASDAQ: BYSI) is a global clinical-stage biopharmaceutical company focused on developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. The Company is advancing its first-in-class lead asset, Plinabulin, as a direct anti-cancer agent in various cancer indications and to prevent chemotherapy-induced neutropenia. Its pipeline also includes three preclinical immuno-oncology assets. Additionally, BeyondSpring's subsidiary, SEED Therapeutics, leverages a proprietary targeted protein degradation (TPD) drug discovery platform and has an initial R&D collaboration with Eli Lilly. Learn more by visiting https://beyondspringpharma.com.
关于 BeyondSpring
BeyondSpring 纳斯达克股票代码：BYSI）是一家处于临床阶段的全球生物制药公司，专注于开发创新疗法，以改善医疗需求未得到满足的患者的临床疗效。该公司正在推进其首创的领先资产Plinabulin，将其作为各种癌症适应症的直接抗癌药物，并预防化疗诱发的中性粒细胞减少症。它是 管道 还包括三种临床前免疫肿瘤学资产。此外，BeyondSpring的子公司SEED Therapeutics利用专有的靶向蛋白降解（TPD）药物发现平台，并与礼来公司进行了初步的研发合作。要了解更多信息，请访问 https://beyondspringpharma.com。
Investor Contact:
IR@beyondspringpharma.com
投资者联系人：
IR@beyondspringpharma.com
Media Contact:
PR@beyondspringpharma.com